PT2388007E - Composição tópica para utilização no tratamento de vermelhidão induzida por rosácea - Google Patents

Composição tópica para utilização no tratamento de vermelhidão induzida por rosácea Download PDF

Info

Publication number: PT2388007E
Authority: PT; Portugal
Prior art keywords: independently hydrogen; rosacea; alkyl; treatment; alkoxy
Prior art date: 2003-05-27

Application number

PT111755781T

Other languages

English (en)

Inventor

Thomas M Rossi

Jack A Dejovin

Original Assignee

Galderma Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-27

Filing date

2004-05-26

Publication date

2015-10-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33457481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2388007(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-26 Application filed by Galderma Pharma Sa filed Critical Galderma Pharma Sa

2015-10-14 Publication of PT2388007E publication Critical patent/PT2388007E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

PT111755781T 2003-05-27 2004-05-26 Composição tópica para utilização no tratamento de vermelhidão induzida por rosácea PT2388007E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47361103P	2003-05-27	2003-05-27
US10/853,585 US7439241B2 (en)	2003-05-27	2004-05-25	Compounds, formulations, and methods for treating or preventing rosacea

Publications (1)

Publication Number	Publication Date
PT2388007E true PT2388007E (pt)	2015-10-14

Family

ID=33457481

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT111755781T PT2388007E (pt)	2003-05-27	2004-05-26	Composição tópica para utilização no tratamento de vermelhidão induzida por rosácea
PT141796425T PT2815748T (pt)	2003-05-27	2004-05-26	Composição tópica para utilização no tratamento de vermelhidão induzida por rosácea
PT04753601T PT1631293E (pt)	2003-05-27	2004-05-26	Compostos, formulações e métodos para tratar ou prevenir a rosácea

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PT141796425T PT2815748T (pt)	2003-05-27	2004-05-26	Composição tópica para utilização no tratamento de vermelhidão induzida por rosácea
PT04753601T PT1631293E (pt)	2003-05-27	2004-05-26	Compostos, formulações e métodos para tratar ou prevenir a rosácea

Country Status (22)

Country	Link
US (13)	US7439241B2 (pt)
EP (3)	EP1631293B2 (pt)
CN (4)	CN101816793B (pt)
AT (1)	ATE530185T1 (pt)
AU (1)	AU2004242967C1 (pt)
CA (1)	CA2530938C (pt)
CY (3)	CY1112242T1 (pt)
DK (3)	DK2815748T3 (pt)
ES (3)	ES2547336T3 (pt)
FR (1)	FR14C0056I2 (pt)
HR (1)	HRP20150957T1 (pt)
HU (3)	HUE027616T2 (pt)
IL (1)	IL172612A (pt)
LT (1)	LT2815748T (pt)
LU (1)	LU92462I2 (pt)
MX (1)	MXPA05014107A (pt)
NO (1)	NO333468B1 (pt)
NZ (1)	NZ544300A (pt)
PL (3)	PL2388007T4 (pt)
PT (3)	PT2388007E (pt)
SI (3)	SI1631293T2 (pt)
WO (1)	WO2004105703A2 (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040266776A1 (en) *	2003-06-25	2004-12-30	Gil Daniel W.	Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) *	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) *	2003-05-27	2013-04-02	Galderma Laboratories Inc.	Methods and compositions for treating or preventing erythema
US20050020600A1 (en) *	2003-07-23	2005-01-27	Scherer Warren J.	Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) *	2004-01-22	2010-10-12	Vicept Therapeutics, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CN104490884A (zh) *	2004-05-25	2015-04-08	桑斯罗萨医药发展公司	治疗或预防炎症性皮肤疾病的化合物、制剂及方法
EP1846007A1 (en) *	2005-01-31	2007-10-24	Robert D. Kross	Skin-protective polymer for use in teat care compositions
DE202005002183U1 (de)	2005-02-04	2005-04-14	Beiersdorf Ag	Hautverwöhnende Cremelotion
US8580317B2 (en) *	2005-03-30	2013-11-12	Revance Therapeutics, Inc.	Compositions and methods for treating acne
EP2656860B1 (en)	2005-06-17	2021-05-05	Wisconsin Alumni Research Foundation	Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
WO2007002447A2 (en) *	2005-06-23	2007-01-04	Bioform Medical, Inc.	Compositions for treating rosacea
FR2894474B1 (fr) *	2005-12-12	2008-04-11	Galderma Res & Dev	Gel depigmentant hydroalcoolique
WO2008144399A1 (en) *	2007-05-18	2008-11-27	Bausch & Lomb Incorporated	COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
US20090060852A1 (en) *	2007-07-27	2009-03-05	Jack Dejovin	Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging
US20090061020A1 (en) *	2007-08-31	2009-03-05	Theobald Klaus P	Brimonidine Compositions for Treating Erythema
MX2010005331A (es)	2007-11-16	2010-08-11	Vicept Therapeutics Inc	Composiciones y metodos para tratamiento de purpura.
BRPI0822095A2 (pt) *	2007-12-21	2014-10-07	Galderma Lab Inc	Método para reduzir o sangramento e/ou hematoma em um paciente
IE20070935A1 (en) *	2007-12-21	2009-06-24	Trinity College Dublin	Guanidine based compounds and their use in the treatment of mental and neurological disorders.
US20100197694A1 (en) *	2008-08-01	2010-08-05	Gerald Horn	Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US8338421B2 (en)	2008-08-01	2012-12-25	Alpha Synergy Development, Inc.	Compositions and methods for reversing rebound hyperemia
US12246013B2 (en)	2008-08-01	2025-03-11	Eye Therapies Llc	Vasoconstriction compositions and methods of use
WO2010085753A1 (en) *	2009-01-23	2010-07-29	Jr Chem, Llc	Rosacea treatments and kits for performing them
FR2942138A1 (fr) *	2009-02-16	2010-08-20	Galderma Res & Dev	Association de composes pour le traitement ou la prevention des affections dermatologiques
KR101859486B1 (ko) *	2009-05-15	2018-06-28	레크로파마, 인코포레이티드	설하용 덱스메데토미딘 조성물과 그의 사용 방법
US8299079B2 (en)	2009-05-22	2012-10-30	Kaufman Herbert E	Preparations and methods for ameliorating or reducing presbyopia
RU2530604C2 (ru) *	2009-05-29	2014-10-10	Галдерма Ресерч Энд Девелопмент	Инъецируемая комбинация агонистов адренергических рецепторов с наполнителями для уменьшения кожных реакций на инъекцию
AU2010313643B2 (en) *	2009-10-26	2015-11-12	Galderma Pharma S.A.	Methods of treating or preventing acute erythema
EP2329849B1 (en) *	2009-11-18	2015-04-29	Galderma Research & Development	Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
US20110172180A1 (en)	2010-01-13	2011-07-14	Allergan Industrie. Sas	Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en)	2010-01-13	2015-08-25	Allergan, Industrie, S.A.S.	Stable hydrogel compositions including additives
WO2011117378A2 (en) *	2010-03-26	2011-09-29	Galderma Research & Development	Improved methods and compositions for safe and effective treatment of telangiectasia
JP5747391B2 (ja) *	2010-03-26	2015-07-15	ガルデルマ・リサーチ・アンド・デヴェロップメント	紅斑の安全かつ有効な治療のための改善された方法および組成物
CA2810746A1 (en)	2010-06-30	2012-01-05	Galderma Research & Development	Method for preventing or treating skin tumor
CN104288768A (zh) *	2010-06-30	2015-01-21	盖尔德马研究及发展公司	α2-肾上腺素能受体激动剂的用途
CN103140217B (zh) *	2010-08-06	2015-08-19	盖尔德马研究及发展公司	用于治疗或预防皮肤病的化合物的组合
US8492422B2 (en) *	2010-09-16	2013-07-23	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
US20120082625A1 (en) *	2010-09-28	2012-04-05	Michael Graeber	Combination treatment for rosacea
US20120076738A1 (en) *	2010-09-28	2012-03-29	Michael Graeber	Combination treatment for dermatological conditions
KR20130101552A (ko) *	2010-10-21	2013-09-13	갈데르마 소시에떼아노님	국소용 겔 조성물
US8053427B1 (en) *	2010-10-21	2011-11-08	Galderma R&D SNC	Brimonidine gel composition
FR2966365B1 (fr) *	2010-10-21	2012-11-09	Galderma Sa	Composition de gel topique
NO2444068T3 (pt)	2010-10-21	2014-12-20
FR2966366B1 (fr) *	2010-10-21	2012-11-09	Galderma Sa	Composition de gel de brimonidine
RU2013124526A (ru) *	2010-11-16	2014-12-27	Аллерган, Инк.	Фармацевтические композиции, содержащие (3-(1-(1н-имидазол-4-ил)этил)-2-метилфенил) метанол
CA2819633C (en) *	2010-12-03	2019-04-23	Allergan, Inc.	Pharmaceutical cream compositions and methods of use
SG190859A1 (en)	2010-12-20	2013-07-31	Colgate Palmolive Co	Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
WO2012083397A1 (en)	2010-12-22	2012-06-28	Silvestre Labs Químia E Farmaceutica Ltda.	Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
BR112013020770A2 (pt) *	2011-02-15	2019-08-27	Allergan Inc	composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea
CN102260608B (zh) *	2011-06-23	2012-07-04	江苏安惠生物科技有限公司	灵芝肥皂及其制备方法
BR112014000876A2 (pt) *	2011-07-14	2017-02-21	Allergan Inc	composições em gel de oximetazolina e métodos de uso
WO2013016072A1 (en) *	2011-07-22	2013-01-31	Allergan, Inc.	Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
CA2850964C (en)	2011-10-05	2021-02-02	Jennifer L. Sanders	Methods and compositions for treating foot or hand pain
US20150044148A1 (en)	2011-10-19	2015-02-12	Galderma Laboratories, Inc.	Method for Treating Capillary Hemangiomas
US9744168B2 (en)	2011-10-19	2017-08-29	Galderma Laboratories, Inc.	Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
UA109359C2 (xx) *	2011-11-10	2015-08-10		Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en)	2011-11-10	2016-03-15	Allergan, Inc.	Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
AU2012340806B2 (en)	2011-11-21	2017-10-19	Allergan, Inc.	Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
SG11201403094TA (en)	2011-12-11	2014-10-30	Recro Pharma Inc	Intranasal dexmedetomidine compositions and methods of use thereof
WO2013115844A1 (en) *	2012-02-02	2013-08-08	Alpha Synergy Development, Inc.	Compositions and methods for treatment of glaucoma
FR3000398A1 (fr) *	2012-12-31	2014-07-04	Galderma Res & Dev	Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3000397A1 (fr)	2012-12-31	2014-07-04	Galderma Res & Dev	Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
AU2013201465B2 (en)	2012-10-24	2016-03-03	Rayner Intraocular Lenses Limited	Stable preservative-free mydriatic and anti-inflammatory solutions for injection
KR20150098675A (ko) *	2012-12-24	2015-08-28	라모트 앳 텔-아비브 유니버시티 리미티드	넌센스 돌연변이로부터 생긴 유전적 질환을 치료하기 위한 물질 및 이를 확인하는 방법
US9861645B2 (en)	2012-12-28	2018-01-09	Rak Holdings Llc	Anti-itch scalp treatment compositions and combinations
WO2014182610A2 (en)	2013-05-06	2014-11-13	Allergan, Inc.	Alpha adrenergic agonists for the treatment of tissue trauma
CN105579042A (zh) *	2013-07-26	2016-05-11	格拉德曼研究与发展公司	治疗皮肤增厚的方法
RU2648449C2 (ru)	2013-10-07	2018-03-26	ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.	Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
KR101831290B1 (ko)	2013-10-07	2018-02-22	테이코쿠 팔마 유에스에이, 인코포레이티드	덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
RU2646512C2 (ru)	2013-10-07	2018-03-05	ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.	Устройства для трансдермальной доставки дексмедетомидина и способы их применения
FR3015288B1 (fr)	2013-12-19	2016-02-12	Galderma Res & Dev	Utilsation du naratriptan dans le traitement de la rosacee
ES2796871T3 (es)	2014-06-11	2020-11-30	Epi Health Llc	Formulaciones de oximetazolina estabilizadas y sus usos
EP2962689B1 (en)	2014-06-30	2018-04-11	Galderma S.A.	Method of treating flushing associated with carcinoid tumors and carcinoid syndrome
RU2560698C1 (ru) *	2014-08-15	2015-08-20	Общество с ограниченной ответственностью "Уральский медико-химический центр" (ООО "УМХЦ")	Средство наружной терапии больных акне
US9351945B1 (en) *	2015-02-27	2016-05-31	John Daniel Dobak, III	Reduction of adipose tissue
US9937117B2 (en)	2015-07-09	2018-04-10	Galderma S.A.	Method of reducing hair loss associated with chemotherapy
FR3041537B1 (fr) *	2015-09-29	2018-11-30	Galderma Research & Development	Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
WO2017085226A1 (en) *	2015-11-17	2017-05-26	Galderma Sa	Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
EP3434271B1 (en)	2016-03-22	2020-08-26	Doris Maria Hexsel	Use of pharmaceutical composition for the treatment of poikiloderma of civatte
EP3476393A4 (en) *	2016-06-28	2019-07-17	Doris Maria Hexsel	USE OF AN ACTIVE AGENT FOR THE TREATMENT OF TELANGIEKTATISCHEM MELASMA
RU2723761C1 (ru)	2016-10-31	2020-06-17	ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.	Способы устранения боли с использованием устройств для трансдермальной доставки дексмедетомидина
CN109265448B (zh) *	2018-11-15	2020-09-15	三峡大学	一类含叔丁基的n-咪唑乙酰基二氢喹喔啉类衍生物，合成方法及其作为杀菌剂上的应用
CA3130437A1 (en) *	2019-02-19	2020-08-27	Sol-Gel Technologies Ltd.	Method for treatment of rosacea
AU2020264808B2 (en)	2019-05-01	2025-01-02	Clexio Biosciences Ltd.	Methods of treating pruritus
US20220211672A1 (en)	2019-05-01	2022-07-07	Clexio Biosciences Ltd.	Methods of treating pruritus
WO2022047042A1 (en) *	2020-08-26	2022-03-03	Oticara, Inc.	Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation
RU2766973C1 (ru) *	2021-10-05	2022-03-16	Татьяна Сергеевна Русина	Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа
WO2023130086A1 (en) *	2021-12-31	2023-07-06	Jss Research, Llc	Compositions and methods for topical treatment of vascular conditions

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3278447A (en)	1963-12-02	1966-10-11	Cloro Bac Products Inc	Process for stabilizing chlorine dioxide solution
US3560501A (en)	1966-09-15	1971-02-02	Ciba Geigy Corp	Process for making dihydroquinazolines
US3723432A (en)	1968-11-12	1973-03-27	Sandoz Ag	1-substituted-4-aryl-2(1h)-quinazolinones and their preparation
US3594380A (en)	1969-02-18	1971-07-20	American Home Prod	Isoquinolin-1(2h)-ones
BE766039A (fr)	1971-04-21	1971-09-16	Labofina Sa	Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.
US3740442A (en)	1972-01-14	1973-06-19	Sandoz Ag	2-isopropylaminobenzophenones in treating inflammation
US4029792A (en)	1972-02-29	1977-06-14	Pfizer Inc.	(2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr)	1972-02-29	1973-08-27	Pfizer	Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en)	1973-09-24	1979-08-14	David Clough	Stabilized aqueous catecholamine solutions
US4201211A (en)	1977-07-12	1980-05-06	Alza Corporation	Therapeutic system for administering clonidine transdermally
US4285967A (en)	1978-06-30	1981-08-25	Estee Lauder Inc.	Cosmetic preparation for reducing redness of blemishes
US4254145A (en) *	1978-08-16	1981-03-03	American Cyanamid Company	Topical application of prostaglandin hypotensive agents
US4256763A (en) *	1978-09-19	1981-03-17	Mchugh John E	Treatment of herpes simplex infections and acne
DE2924005C2 (de) *	1979-06-13	1984-07-05	Sanol Schwarz-Monheim Gmbh, 4019 Monheim	Isosorbiddinitrat enthaltendes Mittel
US5166331A (en)	1983-10-10	1992-11-24	Fidia, S.P.A.	Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en)	1988-06-06	1990-03-13	The Regents Of The University Of California	Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en)	1988-11-29	1995-03-21	Anthony J. Dziabo, Jr.	Aqueous ophthalmic solutions and method for preserving same
US5077292A (en)	1989-10-12	1991-12-31	Allergan, Inc.	(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5204347A (en)	1989-10-12	1993-04-20	Allergan, Inc.	Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5198442A (en)	1989-10-12	1993-03-30	Allergan, Inc.	(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5326763A (en)	1989-10-12	1994-07-05	Allergan, Inc.	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5112822A (en)	1989-10-12	1992-05-12	Allergan, Inc.	(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en)	1989-10-31	1991-06-04	Allergan, Inc.	Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5130441A (en)	1990-02-06	1992-07-14	Allergan, Inc.	Method for producing amino-2-imidazoline derivatives
US5237072A (en)	1990-02-06	1993-08-17	Allergan, Inc.	Method for producing amino-2-imidazoline derivatives
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5326566A (en) *	1991-05-17	1994-07-05	Bristol-Myers Squibb Company	Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
IT1248014B (it) *	1991-06-07	1995-01-05	Inverni Della Beffa Spa	Preparazioni oftalmiche a rilascio protratto
US5292517A (en) *	1992-02-25	1994-03-08	Allergan, Inc.	pH sensitive, reversible gelling, copolymeric erodible drug delivery system
US5736165A (en)	1993-05-25	1998-04-07	Allergan	In-the-eye use of chlorine dioxide-containing compositions
US6323204B1 (en)	1993-10-13	2001-11-27	Allergan	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
JP3683908B2 (ja)	1993-10-13	2005-08-17	アラーガン、インコーポレイテッド	（２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
US6117871A (en)	1993-12-17	2000-09-12	The Procter & Gamble Company	6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6350781B1 (en) *	1994-01-14	2002-02-26	Lee Shahinia, Jr.	Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
WO1996013267A2 (en)	1994-10-27	1996-05-09	Allergan	Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US5688808A (en)	1994-12-22	1997-11-18	Ligand Pharmaceuticals Incorporated	Steroid receptor modulator compounds and methods
WO1996025163A1 (en)	1995-02-14	1996-08-22	Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center	Treatment of herpes simplex viruses
US5620416A (en) *	1995-06-07	1997-04-15	North Carolina State University	Methods of using topical agents with systemically administered active agents
US6194415B1 (en)	1995-06-28	2001-02-27	Allergan Sales, Inc.	Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en)	1995-10-04	1998-02-24	Au Pharmaceuticals, Inc.	Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en)	1995-11-17	2002-08-27	Alcon Manufacturing Ltd..	Combination therapy for treating glaucoma
US5910312A (en) *	1996-10-09	1999-06-08	Ideal Ideas, Inc.	Acne treatment composition with vasoconstrictor
US5916574A (en) *	1996-10-09	1999-06-29	Ideal Ideas, Inc.	Method of treating natural poison skin conditions
US5753637A (en)	1996-10-09	1998-05-19	Ideal Ideas, Inc.	Method of treating acne conditions
EP0969790A2 (de)	1997-02-21	2000-01-12	Beiersdorf Aktiengesellschaft	Zubereitungen für die behandlung von rosacea
JP2001519815A (ja) *	1997-04-10	2001-10-23	エイジェニックス・インコーポレイテッド	アレルゲン誘発性障害の治療におけるラクトフェリンの使用
JPH1129482A (ja)	1997-05-14	1999-02-02	Taisho Pharmaceut Co Ltd	医薬組成物
US6513247B1 (en) *	1997-05-29	2003-02-04	Ariel Krasik-Geiger	Calibrated angle and depth scissors
US6159944A (en)	1998-02-27	2000-12-12	Synchroneuron, Llc	Method for treating painful conditions of the anal region and compositions therefor
US6432934B1 (en) *	1998-08-06	2002-08-13	Advanced Vision Research	Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
AR020660A1 (es)	1998-09-30	2002-05-22	Alcon Lab Inc	Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US20030087962A1 (en)	1998-10-20	2003-05-08	Omeros Corporation	Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
WO2004073708A1 (en) *	1998-12-17	2004-09-02	Dean Thomas R	Brinzolamide and brimonidine for treating ocular conditions
US6258350B1 (en) *	1999-01-20	2001-07-10	Alcon Manufacturing, Ltd.	Sustained release ophthalmic formulation
IN185228B (pt)	1999-02-03	2000-12-09	Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en)	1999-02-22	2002-12-26	Schultz Clyde L.	Drug delivery system for anti-glaucomatous medication
AU5331200A (en)	1999-06-11	2001-01-02	Ohio State University Research Foundation, The	Methods and compositions for treating raynaud's phenomenon and scleroderma
US6340681B1 (en)	1999-07-16	2002-01-22	Pfizer Inc	2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6147102A (en)	1999-10-26	2000-11-14	Curatek Pharmaceuticals Holding, Inc.	Clonidine preparations
US20030077301A1 (en)	1999-12-16	2003-04-24	Maibach Howard I.	Topical pharmaceutical composition for the treatment of inflammatory dermatoses
TR200402292T4 (tr) *	2000-01-31	2004-12-21	Pfizer Products Inc.	PDE4 izozimlerinin inhibitörleri olarak pirimidin karboksamidler.
US6294553B1 (en) *	2000-02-15	2001-09-25	Allergan Sales, Inc.	Method for treating ocular pain
US6284765B1 (en)	2000-04-27	2001-09-04	The University Of North Texas Health Science Center At Fort Worth	(+) naloxone and epinephrine combination therapy
US6444681B1 (en)	2000-06-09	2002-09-03	The Ohio State University Research Foundation	Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6468989B1 (en)	2000-07-13	2002-10-22	Dow Pharmaceutical Sciences	Gel compositions containing metronidazole
RU2311928C2 (ru)	2000-07-14	2007-12-10	Аллерган Инк.	Композиции, содержащие альфа-2-адренергические агонисты
US6387383B1 (en)	2000-08-03	2002-05-14	Dow Pharmaceutical Sciences	Topical low-viscosity gel composition
US7498303B2 (en)	2000-10-30	2009-03-03	University Of Zuerich	GNRH analogues for treatment of urinary incontinence
US7211267B2 (en)	2001-04-05	2007-05-01	Collagenex Pharmaceuticals, Inc.	Methods of treating acne
WO2002089743A2 (en) *	2001-05-09	2002-11-14	The Regents Of The University Of Michigan	Use of compositions for treating rosacea
TNSN02063A1 (en) *	2001-07-07	2005-12-23	Egyptian Natural Oil Co Natoil	The medical effect of jojoba oil
US7115724B2 (en) *	2001-08-22	2006-10-03	Wyeth	Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor
US7704530B2 (en) *	2001-09-14	2010-04-27	Kenji Nakamura	Antimicrobially treated material and methods of preventing coloring thereof
US6680062B2 (en)	2001-10-05	2004-01-20	Color Access, Inc.	Anti-irritating rosacea treatment
US20040266776A1 (en)	2003-06-25	2004-12-30	Gil Daniel W.	Methods of preventing and reducing the severity of stress-associated conditions
US7345065B2 (en) *	2002-05-21	2008-03-18	Allergan, Inc.	Methods and compositions for alleviating pain
US20040092482A1 (en)	2002-11-07	2004-05-13	Gupta Shyam K.	Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en)	2003-02-10	2004-08-12	Gupta Shyam K.	Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en)	2003-04-04	2004-11-04	Yu Ruey J.	Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
EP1622554A4 (en)	2003-05-15	2008-01-02	Bioform Medical Inc	COMPOSITIONS CONTAINING A COMBINATION OF A PHARMACEUTICAL AGENT OR A COSMETIC AGENT AND AN OXY-GROUP-WEARING AROMATIC ALDEHYDE
US7439241B2 (en) *	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) *	2003-05-27	2013-04-02	Galderma Laboratories Inc.	Methods and compositions for treating or preventing erythema
US20050020600A1 (en) *	2003-07-23	2005-01-27	Scherer Warren J.	Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
FR2862537B1 (fr) †	2003-11-21	2006-03-03	Galderma Res & Dev	Utilisation du fepradinol pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
US7812049B2 (en)	2004-01-22	2010-10-12	Vicept Therapeutics, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CN104490884A (zh) *	2004-05-25	2015-04-08	桑斯罗萨医药发展公司	治疗或预防炎症性皮肤疾病的化合物、制剂及方法
AU2007219040B2 (en) *	2006-02-20	2012-01-19	Commonwealth Scientific And Industrial Research Organisation	Method and composition for priming wood and natural fibres
CN101795677B (zh) *	2007-05-09	2012-11-14	沙路特里亚制药有限责任公司	用于治疗炎性病症的螺环化合物
US20090061020A1 (en) *	2007-08-31	2009-03-05	Theobald Klaus P	Brimonidine Compositions for Treating Erythema
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
JP5747391B2 (ja) *	2010-03-26	2015-07-15	ガルデルマ・リサーチ・アンド・デヴェロップメント	紅斑の安全かつ有効な治療のための改善された方法および組成物
US8053427B1 (en) *	2010-10-21	2011-11-08	Galderma R&D SNC	Brimonidine gel composition

2004
- 2004-05-25 US US10/853,585 patent/US7439241B2/en not_active Expired - Lifetime
- 2004-05-26 WO PCT/US2004/016799 patent/WO2004105703A2/en not_active Ceased
- 2004-05-26 SI SI200431808T patent/SI1631293T2/sl unknown
- 2004-05-26 AT AT04753601T patent/ATE530185T1/de active
- 2004-05-26 LT LTEP14179642.5T patent/LT2815748T/lt unknown
- 2004-05-26 PL PL11175578T patent/PL2388007T4/pl unknown
- 2004-05-26 DK DK14179642.5T patent/DK2815748T3/da active
- 2004-05-26 NZ NZ544300A patent/NZ544300A/en not_active IP Right Cessation
- 2004-05-26 DK DK11175578.1T patent/DK2388007T3/en active
- 2004-05-26 SI SI200432500T patent/SI2815748T1/sl unknown
- 2004-05-26 PL PL04753601T patent/PL1631293T5/pl unknown
- 2004-05-26 HU HUE11175578A patent/HUE027616T2/en unknown
- 2004-05-26 ES ES11175578.1T patent/ES2547336T3/es not_active Expired - Lifetime
- 2004-05-26 CN CN2010101707878A patent/CN101816793B/zh not_active Expired - Lifetime
- 2004-05-26 PT PT111755781T patent/PT2388007E/pt unknown
- 2004-05-26 EP EP04753601.6A patent/EP1631293B2/en not_active Expired - Lifetime
- 2004-05-26 CN CN2004800217075A patent/CN1829518B/zh not_active Expired - Lifetime
- 2004-05-26 MX MXPA05014107A patent/MXPA05014107A/es active IP Right Grant
- 2004-05-26 AU AU2004242967A patent/AU2004242967C1/en not_active Expired
- 2004-05-26 EP EP14179642.5A patent/EP2815748B1/en not_active Expired - Lifetime
- 2004-05-26 SI SI200432265T patent/SI2388007T1/sl unknown
- 2004-05-26 CN CN2008101674913A patent/CN101380321B/zh not_active Expired - Lifetime
- 2004-05-26 CA CA2530938A patent/CA2530938C/en not_active Expired - Fee Related
- 2004-05-26 PT PT141796425T patent/PT2815748T/pt unknown
- 2004-05-26 PL PL14179642T patent/PL2815748T3/pl unknown
- 2004-05-26 CN CN201210033288.3A patent/CN102743380B/zh not_active Expired - Fee Related
- 2004-05-26 DK DK04753601.6T patent/DK1631293T4/en active
- 2004-05-26 PT PT04753601T patent/PT1631293E/pt unknown
- 2004-05-26 ES ES14179642T patent/ES2812532T3/es not_active Expired - Lifetime
- 2004-05-26 EP EP11175578.1A patent/EP2388007B1/en not_active Expired - Lifetime
- 2004-05-26 ES ES04753601.6T patent/ES2376172T5/es not_active Expired - Lifetime
- 2004-05-26 HU HUE14179642A patent/HUE051833T2/hu unknown
2005
- 2005-05-25 US US11/137,911 patent/US20050276830A1/en not_active Abandoned
- 2005-12-15 IL IL172612A patent/IL172612A/en active IP Right Grant
- 2005-12-21 NO NO20056104A patent/NO333468B1/no unknown
- 2005-12-29 US US11/321,093 patent/US20060171974A1/en not_active Abandoned
2006
- 2006-06-08 US US11/449,079 patent/US7838563B2/en active Active
2009
- 2009-08-20 US US12/544,663 patent/US8231885B2/en not_active Expired - Lifetime
- 2009-08-21 US US12/545,638 patent/US8426410B2/en not_active Expired - Fee Related
- 2009-11-18 US US12/620,982 patent/US20100130502A1/en not_active Abandoned
2012
- 2012-01-17 CY CY20121100049T patent/CY1112242T1/el unknown
- 2012-07-10 US US13/545,566 patent/US8557817B2/en not_active Expired - Fee Related
2013
- 2013-02-25 US US13/775,784 patent/US8859551B2/en not_active Expired - Lifetime
- 2013-02-25 US US13/775,861 patent/US8993571B2/en not_active Expired - Lifetime
2014
- 2014-05-28 LU LU92462C patent/LU92462I2/xx unknown
- 2014-06-02 HU HUS1400029C patent/HUS1400029I1/hu unknown
- 2014-07-22 FR FR14C0056C patent/FR14C0056I2/fr active Active
- 2014-07-31 CY CY2014028C patent/CY2014028I2/el unknown
2015
- 2015-03-30 US US14/672,704 patent/US20150202202A1/en not_active Abandoned
- 2015-09-10 HR HRP20150957TT patent/HRP20150957T1/hr unknown
2016
- 2016-04-06 US US15/091,703 patent/US20160220565A1/en not_active Abandoned
2017
- 2017-04-13 US US15/486,353 patent/US20170216282A1/en not_active Abandoned
2020
- 2020-08-18 CY CY20201100775T patent/CY1123393T1/el unknown

Also Published As

Publication number	Publication date
CY1112242T1 (el)	2015-12-09
CA2530938A1 (en)	2004-12-09
PL2388007T3 (pl)	2016-01-29
US20050276830A1 (en)	2005-12-15
US8557817B2 (en)	2013-10-15
LU92462I2 (fr)	2015-11-02
US20120277241A1 (en)	2012-11-01
US7439241B2 (en)	2008-10-21
HK1204996A1 (en)	2015-12-11
WO2004105703A3 (en)	2005-03-17
HK1164126A1 (en)	2012-09-21
CY1123393T1 (el)	2021-12-31
US20100021402A1 (en)	2010-01-28
US20130172358A1 (en)	2013-07-04
PT2815748T (pt)	2020-08-31
FR14C0056I1 (pt)	2014-08-22
HRP20150957T1 (hr)	2015-11-20
EP1631293A4 (en)	2009-05-06
ES2376172T3 (es)	2012-03-09
EP2815748A1 (en)	2014-12-24
ES2812532T3 (es)	2021-03-17
EP1631293A2 (en)	2006-03-08
CN102743380B (zh)	2015-08-12
CA2530938C (en)	2011-12-13
HUE051833T2 (hu)	2021-03-29
PL1631293T3 (pl)	2012-03-30
EP2815748B1 (en)	2020-08-05
MXPA05014107A (es)	2006-03-17
US8993571B2 (en)	2015-03-31
NZ544300A (en)	2009-03-31
PL2815748T3 (pl)	2020-11-16
FR14C0056I2 (fr)	2016-12-23
PT1631293E (pt)	2012-02-01
US20130172359A1 (en)	2013-07-04
US8859551B2 (en)	2014-10-14
CY2014028I1 (el)	2015-12-09
PL2388007T4 (pl)	2016-03-31
US8231885B2 (en)	2012-07-31
CN102743380A (zh)	2012-10-24
IL172612A (en)	2013-03-24
US20060264515A1 (en)	2006-11-23
SI1631293T1 (sl)	2012-02-29
CN101380321A (zh)	2009-03-11
CN101816793A (zh)	2010-09-01
DK2388007T3 (en)	2015-09-28
US20040242588A1 (en)	2004-12-02
SI1631293T2 (sl)	2015-02-27
DK2815748T3 (da)	2020-08-24
US20060171974A1 (en)	2006-08-03
DK1631293T4 (en)	2015-01-12
ES2547336T3 (es)	2015-10-05
CN101816793B (zh)	2012-08-15
CN1829518B (zh)	2010-09-08
DK1631293T3 (da)	2012-02-13
ATE530185T1 (de)	2011-11-15
HK1084591A1 (en)	2006-08-04
AU2004242967B2 (en)	2009-05-28
NO333468B1 (no)	2013-06-17
LT2815748T (lt)	2020-11-25
SI2815748T1 (sl)	2020-11-30
US7838563B2 (en)	2010-11-23
ES2376172T5 (es)	2015-01-08
PL1631293T5 (pl)	2015-04-30
EP1631293B2 (en)	2014-10-08
HUE027616T2 (en)	2016-11-28
CN1829518A (zh)	2006-09-06
EP1631293B1 (en)	2011-10-26
CN101380321B (zh)	2013-03-27
US20160220565A1 (en)	2016-08-04
CY2014028I2 (el)	2015-12-09
US20100227867A1 (en)	2010-09-09
EP2388007A1 (en)	2011-11-23
WO2004105703A2 (en)	2004-12-09
HUS1400029I1 (hu)	2017-10-30
US20170216282A1 (en)	2017-08-03
NO20056104L (no)	2006-02-03
US20100130502A1 (en)	2010-05-27
EP2388007B1 (en)	2015-06-24
AU2004242967A1 (en)	2004-12-09
SI2388007T1 (sl)	2016-01-29
AU2004242967C1 (en)	2015-12-24
US20150202202A1 (en)	2015-07-23
US8426410B2 (en)	2013-04-23

Publication	Publication Date	Title
SI2388007T1 (sl)	2016-01-29	Topikalna sestava za uporabo pri zdravljenju z rozaceo inducirane rdečine
WO2005115395A3 (en)	2009-04-09	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
MXPA05012286A (es)	2006-01-30	Mezclas fungicidas para combatir patogenos de arroz.
DE60136188D1 (de)	2008-11-27	Prolin-derivate und deren verwendung als medikamente
NZ521681A (en)	2006-03-31	Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
WO2005007100A3 (en)	2005-05-06	Pharmaceutical compositions for topical application
BRPI0415203A (pt)	2006-12-05	pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
CA2343459A1 (en)	2001-10-03	Pyrazole derivatives as anti-inflammatory/analgesic agents
WO2006073938A3 (en)	2006-10-12	Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
ES8700049A1 (es)	1986-10-16	Un procedimiento para la preparacion de una composicion topica para reducir la secrecion de sebo
DE60107832D1 (en)	2005-01-20	Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
PT1165485E (pt)	2004-08-31	Processo para a preparacao de produtos intermediarios pesticidas
BR0104359A (pt)	2001-11-27	Decursinol ou seus derivados a partir de agenteanalgésico
WO2004045283A3 (de)	2004-07-29	Fungizide mischungen zur bekämpfung von reispathogenen
BR0206478A (pt)	2003-12-30	Formulações tópicas estabilizadas de brivudina
CY1116690T1 (el)	2017-03-15	Τοπικη συνθεση για χρηση στην θεραπεια της ερυθροτητας που επαγεται απο την ροδοχρωμη ακμη
IL130052A0 (en)	2000-02-29	Method of treating glaucoma and ischemic retinopathy
UA18236A (uk)	1997-12-25	Беhзоат етаhоламіhу як засіб, що підвищує продуктивhість озимої пшеhиці
BR0111864A (pt)	2003-07-01	Processo para a preparação de pirazolopirimidinonas
EA200601452A1 (ru)	2007-02-27	Фунгицидные смеси
MXPA05013393A (es)	2006-03-09	Metodo para inducir el sueno usando administracion topica de agentes vasoactivos.
EA200600966A1 (ru)	2006-10-27	Фунгицидные смеси
BR0212011A (pt)	2004-07-20	Compostos e seus processos de preparação
ITMI942645A1 (it)	1996-06-23	Uso di derivati guanidin-imidazolici per coadiuvare la stimolazione della crescita dei capelli.
ECSP992887A (es)	1999-06-01	Biciclo (2.2.1) heptanos y compuestos relacionados